[Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers]. / Renin-Angiotensin-System (RAS) und COVID-19 Zur Verordnung von RAS-Blockern.
Dtsch Med Wochenschr
; 145(10): 682-686, 2020 05.
Article
in German
| MEDLINE | ID: covidwho-1721664
ABSTRACT
Twenty years ago, an enzyme homologous to the previously known angiotensin-converting enzyme (ACE) was identified, and subsequently named ACE2. In the renin-angiotensin system (RAS), ACE2 has counter-regulatory functions against the classical effector peptide angiotensin II, for example in blood pressure regulation and cardiovascular remodeling. However, ACE2 provides an initially unexpected interesting link between virology and cardiovascular medicine. That is, ACE2 represents the binding receptor for the cellular uptake of SARS-CoV and SARS-CoV-2 viruses. Thus, ACE2 is relevant for COVID-19. In this context, it was suspected that therapy with RAS blockers might promote transmission and complications of COVID-19 by upregulation of ACE2 expression. The aim of this short review is, to describe the link between the RAS, particularly ACE2, and COVID-19. Based on our analysis and evaluation of the available findings, we justify our conclusion:
important drugs such as ACE inhibitors and angiotensin receptor blockers should continue to be prescribed according to guidelines to stable patients in the context of the COVID-19 pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Renin-Angiotensin System
/
Angiotensin-Converting Enzyme Inhibitors
/
Coronavirus Infections
/
Peptidyl-Dipeptidase A
Type of study:
Experimental Studies
Limits:
Humans
Language:
German
Journal:
Dtsch Med Wochenschr
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS